產品中心Cell Resources
聯(lián)系我們CONTACT US
400-999-210024小時服務熱線
產品概述
| 名稱 | SK-OV-3 (人卵巢癌細胞) (STR鑒定正確) |
| 別稱 | SKOV-3; SK.OV.3; SKOV3; Skov3; SKO3 |
| 種屬 | 人 |
| 生長特性 | 貼壁細胞 |
| 細胞形態(tài) | 上皮細胞樣 |
| 凍存條件 | 凍存液：55% 基礎培養(yǎng)基+40%FBS+5%DMSO 溫度：液氮 |
| 培養(yǎng)方案A（默認） |
生長培養(yǎng)基:
培養(yǎng)條件:
氣相：空氣，95%；CO2，5%, 溫度：37℃
|
| 推薦傳代比例 | 1:2-1:4 |
| 推薦換液頻率 | 2-3次/周 |
| 背景描述 | SK-OV-3細胞是由G·Trempe和L·J·Old于1973年從卵巢腫瘤病人的腹水分離得到。SK-OV-3細胞對腫瘤壞死因子和幾種細胞毒性藥物包括白喉毒素、順鉑和阿霉素均耐受。SK-OV-3細胞在裸鼠中致瘤，且形成與卵巢原位癌一致的中度分化的腺癌。 |
| 年齡（性別） | 女性；64歲 |
| 組織來源 | 卵巢腺癌，腹水轉移 |
| 細胞類型 | 腫瘤細胞 |
| 腫瘤類型 | 卵巢癌細胞 |
| 生物安全等級 | BSL-1 |
| 倍增時間 | ~20-48 hours |
| 致瘤性 | Yes, in nude mice; forms moderately well differentiated adenocarcinoma consistent with ovarian primary. |
| 抗原表達情況 | Blood Type B; Rh+ |
| 基因表達情況 | Blood Type B; Rh+ |
| 保藏機構 | ATCC; HTB-77 ECACC; 91091004 |
STR鑒定
-
STR位點信息
Amelogenin X CSF1PO 11 D2S1338 18,23 D3S1358 14 D5S818 11 D7S820 13 D8S1179 14,15 D13S317 8,11 D16S539 12 D18S51 16,17,18 D19S433 14,14.2 D21S11 30,31.2 FGA 24,25 PentaD 12,13 PentaE 5,13 TH01 9,9.3 TPOX 7,11 vWA 17,18 D6S1043 12 D12S391 22 D2S441 10,11.3 -
STR鑒定圖
-
參考文獻
-
An all-in-one tetrazine reagent for cysteine-selective labeling and bioorthogonal activable prodrug construction(2024/04/02)
作者：Xinyu He, Jie Li, Xinxin Liang
期刊：Nature Communications
DOI：10.1038/s41467-024-47188-6
影響因子 ：16.600
引用產品：CL-0215
-
A smart O2-generating nanocarrier optimizes drug transportation comprehensively for chemotherapy improving(2021/03/29)
作者：Xiaojuan Zhang, Chuanchuan He, Yun Sun
期刊：Acta Pharmaceutica Sinica B
DOI：10.1016/j.apsb.2021.04.021
影響因子 ：14.500
引用產品：CL-0215
-
Loss of SMURF2 expression enhances RACK1 stability and promotes ovarian cancer progression(2023/10/12)
作者：Yanan Pi, Qiushi Feng, Fusheng Sun
期刊：CELL DEATH AND DIFFERENTIATION
DOI：10.1038/s41418-023-01226-w
影響因子 ：12.400
引用產品：CL-0215
-
Elevated expression of the rhythm gene NFIL3 promotes the progression of TNBC by activating NF-κB signaling through suppression of NFKBIA transcription(2022/02/18)
作者：Weiwei Yang , Jing Li, Minghui Zhang
期刊：Journal Of Experimental & Clinical Cancer Research
DOI：10.1186/s13046-022-02260-1
影響因子 ：11.300
引用產品：CL-0016 CL-0041 CL-0097 CL-0101 CL-0114 CL-0184 CL-0215 CL-0525
-
Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer(2024/02/26)
作者：Weisong Li, Kai Zhang, Wenjun Wang
期刊：JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
DOI：10.1186/s13046-024-02981-5
影響因子 ：11.300
引用產品：CL-0215
-
A PET Probe Targeting Polyamine Transport System for Precise Tumor Diagnosis and Therapy(2024/04/25)
作者：Ming Zhou, Xiaoqin Yin, Bei Chen
期刊：Asian Journal of Pharmaceutical Sciences
DOI：10.1016/j.ajps.2024.100924
影響因子 ：10.200
引用產品：CL-0215
-
MiR-337–3p suppresses proliferation of epithelial ovarian cancer bytargeting PIK3CA and PIK3CB(2019/10/17)
作者：Zhen Zhang, Luoyan Zhang, Bin Wang
期刊：Cancer Letters
DOI：10.1016/j.canlet.2019.10.021
影響因子 ：9.700
-
A solid lipid coated calcium peroxide nanocarrier enables combined cancer chemo/chemodynamic therapy with O2/H2O2 self-sufficiency(2021/1/6)
作者：Chuanchuan He, Xiaojuan Zhang, Chen Chen
期刊：Acta Biomaterialia
DOI：10.1016/j.actbio.2020.12.036
影響因子 ：9.300
引用產品：CL-0215
-
Combination of Chemotherapy and Photodynamic Therapy with Oxygen Self-Supply in the Form of Mutual Assistance for Cancer Therapy(2023/03/17)
作者：Ying Chen, Lei Zhang, Fangxuan Li
期刊：International Journal of Nanomedicine
影響因子 ：8.000
引用產品：CL-0215
-
IR780-loaded folate-targeted nanoparticles for near-infrared fluorescence image-guided surgery and photothermal therapy in ovarian cancer(2019/04/18)
作者：Jiao Song, Ni Zhang, Liang Zhang
期刊：International Journal of Nanomedicine
影響因子 ：8.000
引用產品：CL-0215
-
GSK3β and UCHL3 govern RIPK4 homeostasis via deubiquitination to enhance tumor metastasis in ovarian cancer(2024/04/25)
作者：Wulin Shan, Wenju Peng, Yao Chen
期刊：ONCOGENE
DOI：10.1038/s41388-024-03040-1
影響因子 ：8.000
引用產品：CL-0215
-
Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization(2017/05/08)
作者：H Guo, Q Zhu, X Yu
期刊：Oncogene
影響因子 ：8.000
-
Diterpenoid honatisine overcomes temozolomide resistance in glioblastoma by inducing mitonuclear protein imbalance through disruption of TFAM-mediated mtDNA transcription(2023/12/29)
作者：Zongyang Li, Ke Sai, Guoxu Ma
期刊：PHYTOMEDICINE
DOI：10.1016/j.phymed.2023.155328
影響因子 ：7.900
引用產品：CL-0215
-
Toosendanin reduces cisplatin resistance in ovarian cancer through modulating the miR-195/ERK/β-catenin pathway(2022/11/25)
作者：Ge Wang, Lu Li, Yan Li, Li-Hong Zhang
期刊：PHYTOMEDICINE
DOI：10.1016/j.phymed.2022.154571
影響因子 ：7.900
引用產品：CL-0215
-
Isothiocyanate Iberin inhibits cell proliferation and induces cell apoptosis in the progression of ovarian cancer by mediating ROS accumulation and GPX1 expression(2021/06/17)
作者：Tingting Gong, Qian Guo, Xiao Li
期刊：Biomedicine & Pharmacotherapy
DOI：10.1016/j.biopha.2021.111533
影響因子 ：7.500
-
A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer(2023/01/30)
作者：Yizhuo Xie, Zhihui Ren, Hongyu Chen
期刊：BIOMEDICINE & PHARMACOTHERAPY
DOI：10.1016/j.biopha.2023.114304
影響因子 ：7.500
引用產品：CL-0215
-
An Activity-Based Fluorogenic Probe Enables Cellular and in Vivo Profiling of Carboxylesterase Isozymes(2020/07/07)
作者：Shiyu Liu, Renyu Qu, Rongrong Li
期刊：Analytical Chemistry
DOI：10.1021/acs.analchem.0c01554
影響因子 ：7.400
-
m6A methylation-mediated regulation of LncRNA MEG3 suppresses ovarian cancer progression through miR-885-5p and the VASH1 pathway(2024/01/29)
作者：Yan Li, Shenghan Lou, Jian Zhang
期刊：Journal of Translational Medicine
DOI：10.1186/s12967-024-04929-x
影響因子 ：7.400
引用產品：CL-0215
-
ZSWIM4 inhibition improves chemosensitivity in epithelial ovarian cancer cells by suppressing intracellular glycine biosynthesis(2024/02/21)
作者：Kunxiang Gong, Yinger Huang, Yanqin Zheng
期刊：Journal of Translational Medicine
DOI：10.1186/s12967-024-04980-8
影響因子 ：7.400
引用產品：CL-0215
-
The application of HER2 and CD47 CAR-macrophage in ovarian cancer(2023/09/22)
作者：Yizhao Chen, Xiangling Zhu, Hanze Liu
期刊：Journal of Translational Medicine
DOI：10.1186/s12967-023-04479-8
影響因子 ：7.400
-
Design, Synthesis, and Antitumor Activity Evaluation of Novel VISTA Small Molecule Inhibitors(2024/02/27)
作者：Chengliang Sun, Yuling He, Gefei Wang
期刊：JOURNAL OF MEDICINAL CHEMISTRY
DOI：10.1021/acs.jmedchem.3c02039
影響因子 ：7.300
引用產品：CL-0215
-
An exosome-derived lncRNA signature identified by machine learning associated with prognosis and biomarkers for immunotherapy in ovarian cancer(2024/02/09)
作者：Yongjia Cui, Weixuan Zhang, Wenping Lu
期刊：Frontiers in Immunology
DOI：10.3389/fimmu.2024.1228235
影響因子 ：7.300
引用產品：CL-0215
-
Design of Selective PARP-1 Inhibitors and Antitumor Studies(2024/05/22)
作者：Yiting Zhang, Xiangqian Li, Fang Liu
期刊：JOURNAL OF MEDICINAL CHEMISTRY
DOI：10.1021/acs.jmedchem.3c02460
影響因子 ：7.300
引用產品：CL-0215
-
Oncogenic microRNA-181d binding to OGT contributes to resistance of ovarian cancer cells to cisplatin(2021/12/08)
作者：Wei Huang, Ling Chen, Kean Zhu
期刊：Cell Death Discovery
DOI：10.1038/s41420-021-00715-6
影響因子 ：7.000
引用產品：CL-0215
-
Knockdown of long non-coding RNA HOTAIR reverses cisplatin resistance of ovarian cancer cells through inhibiting miR-138-5p-regulated EZH2 and SIRT1(2020/4/29)
作者：Yun Zhang, Hao Ai, Xue Fan
期刊：Biological Research
DOI：10.1186/s40659-020-00286-3
影響因子 ：6.700
引用產品：CL-0215
-
Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1/miR-101-3p/ZEB1/PD-L1 axis(2022/11/01)
作者：Yin Lili, Wang Yu
期刊：CANCER IMMUNOLOGY IMMUNOTHERAPY
DOI：10.1007/s00262-022-03305-2
影響因子 ：6.630
引用產品：CL-0215
-
CBX8 Together with SET Facilitates Ovarian Carcinoma Growth and Metastasis by Suppressing the Transcription of SUSD2(2022/11/03)
作者：Yanjie Wu, Yang Duan, Xuanyuan Li
期刊：MOLECULAR CANCER RESEARCH
DOI：10.1158/1541-7786.MCR-22-0139
影響因子 ：6.333
引用產品：CL-0215
-
Co-encapsulation of (?)-epigallocatechin-3-gallate and piceatannol/oxyresveratrol in β-lactoglobulin: effect of ligand–protein binding on the antioxidant activity, stability, solubility and cytotoxicity(2021/06/02)
作者：Tingting Liu, Min Liu, He Liu
期刊：Food & Function
影響因子 ：6.317
引用產品：CL-0215
-
Identification of a novel pyridine derivative with inhibitory activity against ovarian cancer progression in vivo and in vitro(2022/11/18)
作者：Lulu Si, Tianjiao Lai, Junru Zhao
期刊：Frontiers in Pharmacology
DOI：10.3389/fphar.2022.1064485
影響因子 ：5.988
引用產品：CL-0215
-
Cisplatin-loaded mesoporous polydopamine nanoparticles capped with MnO2 and coated with platelet membrane provide synergistic anti-tumor therapy(2024/04/06)
作者：Yanyan Zhang, Gareth R. Williams, Tong Wang
期刊：INTERNATIONAL JOURNAL OF PHARMACEUTICS
DOI：10.1016/j.ijpharm.2024.124093
影響因子 ：5.800
引用產品：CL-0215
-
Wenshenyang recipe treats infertility through hormonal regulation and inflammatory responses revealed by transcriptome analysis and network pharmacology(2022/08/08)
作者：Lan Xie, Shuai Zhao, Xiaoling Zhang
期刊：Frontiers in Pharmacology
影響因子 ：5.600
引用產品：CL-0215
-
Dietary flavonoid tectochrysin synergistically enhances cisplatin sensitivity on ovarian cancer cells through targeting the CDK1/cyclin B1 pathway(2024/05/21)
作者：Shasha Liu, Yuling Guo, Feiya Jiang
期刊：Journal of Functional Foods
影響因子 ：5.600
引用產品：CL-0215
-
Identification of prognostic and diagnostic signatures for cancer and acute myocardial infarction: multi-omics approaches for deciphering heterogeneity to enhance patient management(2023/09/14)
作者：Na Yuan, Haihua Pan, Yanshan Liang
期刊：Frontiers in Pharmacology
DOI：10.3389/fphar.2023.1249145
影響因子 ：5.600
-
Structure-based virtual screening identified novel FOXM1 inhibitors as the lead compounds for ovarian cancer(2022/11/24)
作者：Ziying Zhou, Xiaoyang Han, Lianqi Sun
期刊：Frontiers in Chemistry
DOI：10.3389/fchem.2022.1058256
影響因子 ：5.545
引用產品：CL-0215
-
The anticancer effect of extract of medicinal mushroom Sanghuangprous vaninii against human cervical cancer cell via endoplasmic reticulum stress-mitochondrial apoptotic pathway(2021/6/17)
作者：Pingya He, Yuhao Hou, Yue Yang
期刊：Journal Of Ethnopharmacology
影響因子 ：5.400
-
Signatures of tumor-associated macrophages correlate with treatment response in ovarian cancer patients(2024/01/03)
作者：Yang Gao, Yuwen Qi, Yin Shen
期刊：Aging-US
影響因子 ：5.200
引用產品：CL-0215
-
Portulaca oleracea L. polysaccharide inhibits ovarian cancer via inducing ACSL4-dependent ferroptosis(2024/03/19)
作者：Liping Xia, Mo Yang, Yan Liu
期刊：Aging-US
影響因子 ：5.200
引用產品：CL-0215
-
Knockdown of lncRNA ACTA2-AS1 reverses cisplatin resistance of ovarian cancer cells via inhibition of miR-378a-3p-regulated Wnt5a(2022/04/12)
作者：Chenxiao Lin, Meiyun Zheng, Youlin Yang
期刊：Bioengineered
DOI：10.1080/21655979.2022.2061181
影響因子 ：4.900
引用產品：CL-0215
-
Circular RNA lysophosphatidic acid receptor 3 (circ-LPAR3) enhances the cisplatin resistance of ovarian cancer(2022/01/26)
作者：Xuemei Liu, Zhiping Yin, Yanjun Wu
期刊：Bioengineered
DOI：10.1080/21655979.2022.2029109
影響因子 ：4.900
-
MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer(2021/04/17)
作者：Mengqi Deng, Di Wu, Yanqin Zhang
期刊：Gynecologic Oncology
DOI：10.1016/j.ygyno.2021.04.013
影響因子 ：4.700
-
The roles of autophagy, ferroptosis and pyroptosis in the anti-ovarian cancer mechanism of harmine and their crosstalk(2024/03/18)
作者：Jun Zhu, Hong Zhu, Qing Zhu
期刊：Scientific Reports
DOI：10.1038/s41598-024-57196-7
影響因子 ：4.600
引用產品：CL-0215
-
Therapeutic potential of miRNAs in placental extracellular vesicles in ovarian and endometrial cancer(2023/10/06)
作者：Yi Zhang, Yunhui Tang, Xinyue Chen
期刊：Human Cell
DOI：10.1007/s13577-023-00986-4
影響因子 ：4.300
引用產品：CL-0215
-
CircLNPEP promotes the progression of ovarian cancer through regulating miR-876-3p/ WNT5A axis(2021/08/31)
作者：Wenwen Wang, Weiwei Zhang, Hongjun Guo
期刊：Cell Cycle
DOI：10.1080/15384101.2021.1965723
影響因子 ：4.300
-
KIF26B and CREB3L1 Derived from Immunoscore Could Inhibit the Progression of Ovarian Cancer(2024/02/13)
作者：Shanshan Cong, Yao Fu, Xibo Zhao
期刊：Journal of Immunology Research
影響因子 ：4.100
引用產品：CL-0215
-
Design, synthesis and biological evaluation of rhein–piperazine–furanone hybrids as potential anticancer agents(2024/02/13)
作者：Yu He, Sisi Zhang, Mengxue Wei
期刊：RSC Medicinal Chemistry
影響因子 ：4.100
引用產品：CL-0215
-
The role of OIP5 in the carcinogenesis and progression of ovarian cancer(2023/09/02)
作者：Xin Zhang, Wenjie Gu, Aiqin Lin
期刊：Journal of Ovarian Research
DOI：10.1186/s13048-023-01265-4
影響因子 ：4.000
-
Knockdown of heat shock protein family D member 1 (HSPD1) promotes proliferation and migration of ovarian cancer cells via disrupting the stability of mitochondrial 3-oxoacyl-ACP synthase (OXSM)(2023/04/22)
作者：Yaoyun Duan, Juan Yu, Miaojuan Chen
期刊：Journal of Ovarian Research
DOI：10.1186/s13048-023-01156-8
影響因子 ：4.000
-
CDCA5 promoted cell invasion and migration by activating TGF-β1 pathway in human ovarian cancer cells(2024/03/27)
作者：Qingsong Zhang, Rong Zhang, Yuzhi Li, Xiaojun Yang
期刊：Journal of Ovarian Research
DOI：10.1186/s13048-024-01393-5
影響因子 ：4.000
引用產品：CL-0215
-
CircSETDB1 knockdown inhibits the malignant progression of serous ovarian cancer through miR-129-3p-dependent regulation of MAP3K3(2021/11/17)
作者：Bo Li, Lu Zhang
期刊：Journal of Ovarian Research
DOI：10.1186/s13048-021-00875-0
影響因子 ：4.000
-
Curcumin inhibits ovarian cancer progression by regulating circ-PLEKHM3/miR-320a/SMG1 axis(2021/11/16)
作者：Sifan Sun, Hailiang Fang
期刊：Journal of Ovarian Research
DOI：10.1186/s13048-021-00916-8
影響因子 ：4.000
-
RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis(2021/11/13)
作者：Shengtan Wang, Zaihong Li , Genhai Zhu
期刊：Journal of Ovarian Research
DOI：10.1186/s13048-021-00917-7
影響因子 ：4.000
-
Long non-coding RNA SNHG25 promotes epithelial ovarian cancer progression by up-regulating COMP(2021/1/16)
作者：Yinglei Liu,?Boqun Xu,?Manhua Liu?
期刊：Journal of Cancer
影響因子 ：3.900
引用產品：CL-0215
-
ZNF146 regulates cell cycle progression via TFDP1 and DEPDC1B in ovarian cancer cells(2024/04/01)
作者：Ruixue Zhao, Nana Song, Xin Ning
期刊：REPRODUCTION
影響因子 ：3.800
引用產品：CL-0215
-
The CREB1/WNK1 axis promotes the tumorigenesis of ovarian cancer via regulating HIF-1(2024/04/08)
作者：Yifei Ma, Hui Zong, Pan Pan
期刊：EXPERIMENTAL CELL RESEARCH
DOI：10.1016/j.yexcr.2024.114006
影響因子 ：3.700
引用產品：CL-0215
-
MAPRE3 as an epigenetic target of EZH2 restricts ovarian cancer proliferation in vitro and in vivo(2024/01/08)
作者：Yun Zhang, Fanglin Liu, Jindan Zheng
期刊：EXPERIMENTAL CELL RESEARCH
DOI：10.1016/j.yexcr.2024.113913
影響因子 ：3.700
引用產品：CL-0215
-
Revealing the inhibitory effect of VASH1 on ovarian cancer from multiple perspectives(2023/11/27)
作者：Yan Li, Liang Meng, Ge Lou
期刊：CANCER BIOLOGY & THERAPY
DOI：10.1080/15384047.2023.2285817
影響因子 ：3.600
引用產品：CL-0215
-
Ovarian carcinoma immune-related microRNA affects the heterogeneity of the endocrine microenvironment and anti-tumor immune pattern(2023/10/09)
作者：Kefei Gao, Qing Wang, Pan Xiang
期刊：JOURNAL OF GENE MEDICINE
DOI：10.1002/jgm.3602
影響因子 ：3.500
引用產品：CL-0215
-
miR?576?3p overexpression enhances cisplatin sensitivity of ovarian cancer cells by dysregulating PD?L1 and cyclin D1(2020/11/23)
作者：Ying Zuo, Wei Zheng, Qing Tang
期刊：Molecular Medicine Reports
影響因子 ：3.400
引用產品：CL-0215
-
LPA3 is a precise therapeutic target and potential biomarker for ovarian cancer(2022/01/04)
作者：Pengfei Zhao, Qingru Yun, Aodungerile Li
期刊：Medical Oncology
DOI：10.1007/s12032-021-01616-5
影響因子 ：3.400
引用產品：CL-0215
-
Antiovarian cancer mechanism of esculetin: inducing G0/G1 arrest and apoptosis via JAK2/STAT3 signalling pathway(2022/11/04)
作者：Yin Wen, Fu Xu, Chang Wenwen, Han Li, Meng Jiahao, Cao Aijia, Ren Xiaomin, Fan Zhongxiong, Zhou Suqin
期刊：Journal of Pharmacy and Pharmacology
影響因子 ：3.300
引用產品：CL-0215
-
Screening of CXC chemokines in the microenvironment of ovarian cancer and the biological function of CXCL10(2021/11/18)
作者：Weiyuan Li, Ji-ao Ma, Xun Sheng
期刊：World Journal of Surgical Oncology
DOI：10.1186/s12957-021-02440-x
影響因子 ：3.200
引用產品：CL-0215
-
Norcantharidin induces ferroptosis via the suppression of NRF2/HO?1 signaling in ovarian cancer cells(2022/08/25)
作者：Xiaoyan Zhu, Xiaohong Chen, Longshan Qiu
期刊：Oncology Letters
影響因子 ：2.900
-
ARID5B promoted the histone demethylation of SORBS2 and hampered the metastasis of ovarian cancer(2023/11/03)
作者：Yue Deng, Ying Dong, Lu Wu
期刊：PATHOLOGY RESEARCH AND PRACTICE
影響因子 ：2.800
引用產品：CL-0215
-
Comparative proteomic analysis of the mitochondria of menstrual stem cells and ovarian cancer cells(2023/01/16)
作者：Xiuhui Chen, Wen Zhong, Yue Chang
期刊：Experimental and Therapeutic Medicine
影響因子 ：2.700
引用產品：CL-0215
-
The Antitumor Potential of Extract of the Oak Bracket Medicinal Mushroom Inonotus baumii in SMMC-7721 Tumor Cells(2019/9/22)
作者：Yue Yang, Pingya He, Ning Li
期刊：Evidence-based Complementary and Alternative Medicine
影響因子 ：2.650
-
Lipopolysaccharide-Educated Cancer-Associated Fibroblasts Facilitate Malignant Progression of Ovarian Cancer Cells via the NF-kB/IL-6/JAK2 Signal Transduction(2024/02/02)
作者：Dongjie Wang, Lingchuan Li, Yifeng Zhang, Kefan Ye
期刊：MOLECULAR BIOTECHNOLOGY
DOI：10.1007/s12033-024-01055-3
影響因子 ：2.600
引用產品：CL-0215
-
Down-regulation of DPP4 by TGFβ1/miR29a-3p inhibited proliferation and promoted migration of ovarian cancer cells(2023/10/31)
作者：Chong Liu, Zhaowei Gao, Yingqi Liu
期刊：Discover Oncology
DOI：10.1007/s12672-023-00815-y
影響因子 ：2.200
引用產品：CL-0215
-
Preclinical efficacy of CBR-5884 against epithelial ovarian cancer cells by targeting the serine synthesis pathway(2024/05/11)
作者：Kunxiang Gong, Yinger Huang, Yanqin Zheng
期刊：Discover Oncology
DOI：10.1007/s12672-024-01013-0
影響因子 ：2.200
引用產品：CL-0215
-
MOB kinase activator 1A acts as an oncogene by targeting PI3K/AKT/mTOR in ovarian cancer(2023/06/14)
作者：Jian Lei, Jingying Xu, Min Hu
期刊：Discover Oncology
DOI：10.1007/s12672-023-00705-3
影響因子 ：2.200
引用產品：CL-0215
-
Circ_0021573 acts as a competing endogenous RNA to promote the malignant phenotypes of human ovarian cancer cells(2022/12/05)
作者：Lifang Liu, Bingkai Han, Lixia Liu
期刊：Reproductive Biology
DOI：10.1016/j.repbio.2022.100704
影響因子 ：2.100
引用產品：164210 164210-50 CL-0005 CL-0079 CL-0178 CL-0215 PB180120 PM150110
-
A morpholine derivative N-(4-morpholinomethylene)ethanesulfonamide induces ferroptosis in tumor cells by targeting NRF2(2024/01/30)
作者：Bingchun Sun, Ligang Zhang, Binhua Wu
期刊：BIOLOGICAL & PHARMACEUTICAL BULLETIN
影響因子 ：2.000
引用產品：CL-0215
-
Honokiol regulates ovarian cancer cell malignant behavior through YAP/TAZ pathway modulation(2024/04/04)
作者：Fang Liu, Yufang Zhang, Xinyi Xia
期刊：JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
影響因子 ：1.600
引用產品：CL-0215
-
Honokiol induces ferroptosis in ovarian cancer cells through the regulation of YAP by OTUB2(2024/03/13)
作者：Fang Liu, Yufang Zhang, Xinyi Xia
期刊：JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
影響因子 ：1.600
引用產品：CL-0215
FAQs
Q：{{item.question}}
A：
產品資料
識別碼示意圖
![SCC-25 [SCC 25; SCC25] (人舌鱗癌細胞)(STR鑒定正確)](/Public/upfile/pic/xbx/CL-0569-1.jpg)
